Tirumani Sree Harsha, LaCasce Ann S, Jacene Heather A
Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Lymphoma Program, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, M227, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
PET Clin. 2015 Apr;10(2):207-25. doi: 10.1016/j.cpet.2014.12.005. Epub 2015 Jan 24.
The role of PET and PET/computed tomography (CT) has evolved significantly in the last few decades. 2-Deoxy-2-[18F]-fluoro-d-glucose (FDG)-PET/CT is now an integral part of the management of patients with lymphoma. FDG-PET/CT at the time of initial staging can help in appropriate staging of the patients. Both interim and end-of-therapy PETs have significant prognostic value in patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma and more accurately assess for the presence of residual malignancy than anatomic imaging. The impact of interim FDG-PET/CT on risk-adapted strategies is an area of active investigation and the results of ongoing clinical trials will be informative.
在过去几十年里，正电子发射断层扫描（PET）和PET/计算机断层扫描（CT）的作用有了显著发展。2-脱氧-2-[18F]-氟-D-葡萄糖（FDG）-PET/CT现在是淋巴瘤患者管理中不可或缺的一部分。初始分期时的FDG-PET/CT有助于对患者进行恰当分期。中期和治疗结束时的PET对霍奇金淋巴瘤和侵袭性非霍奇金淋巴瘤患者都具有显著的预后价值，并且比解剖成像更准确地评估残留恶性肿瘤的存在情况。中期FDG-PET/CT对风险适应性策略的影响是一个积极研究的领域，正在进行的临床试验结果将提供有用信息。
